SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at […]
Category Archives: Pr Newswire
20
Mar
Mar
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 […]
20
Mar
Mar
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K announcing its financial results for the fiscal year ended December 31, 2025. Results The Company reported total revenues of $6,715,175 for the […]
Pr Newswire
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
20
Mar
Mar
— First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – — Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic […]
20
Mar
Mar
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include: (CAD) Q4 2025 % Changevs.Q4 2024 FY 2025 % Change vs. FY 2024 Canadian Pharma Sales […]
Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable Tolerability MIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ — Crescel LLC, an innovative science and technology company, today announced results from a double-blind, randomized, active comparator-controlled clinical trial evaluating its biobotanical Skin Renewal Cream compared to a commonly used standard of care—topical metronidazole (Metrocream®) combined with CeraVe® moisturizer—in individuals […]
A Full-Stack, Agent-First Model That Closes the Enterprise AI Deployment Gap NEW YORK and MUMBAI, India, March 20, 2026 /PRNewswire/ — Firstsource Solutions Limited (NSE: FSL) (BSE: 532809), an RP-Sanjiv Goenka Group company, today launched Intelligence That Operates, a full-stack, agent-first operating model to design, build, and run AI-powered enterprise operations — with outcomes underwritten, not […]
OTTAWA, ON, March 20, 2026 /PRNewswire/ — Gastops, an innovative Canadian provider of advanced In-Service Support solutions across marine, aerospace, energy, and industrial applications, has signed a Teaming Agreement with TKMS, a German provider of integrated system solutions in maritime defense technologies with more than 180 years of experience in naval engineering, to support the Canadian […]
SINGAPORE, March 20, 2026 /PRNewswire/ — Mureka, the AI-powered music creation platform developed by Skywork AI, today announced the release of two new capabilities — Studio and Remix — as part of its continued push to redefine how music is imagined, created, and evolved in the age of artificial intelligence. Rather than positioning AI as a […]
Joint Venture with Award-Winning Producer Molly Conners Establishes International Media Fund and Co-Production Platform Across EMEA and APAC ABU DHABI, UAE, MILAN and NEW YORK, March 19, 2026 /PRNewswire/ — Mondevo Group, the AI-native wealth and innovation platform, today announced the formation of Phiphen International, a joint venture between MondeVita — a subsidiary of Mondevo Group […]